Advertisement
Advertisement
RARE
Ultragenyx Pharmaceutical Inc.
23.39
USDSponsored
-0.32
-1.35%
May 22, 16:00 UTC -4
Closed
After-Market
23.39
0.00
0.00%
RARE Earnings Reports
Positive Surprise Ratio
RARE beat 20 of 42 last estimates.
48%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$183.81M
/-$1.23
Implied change from Q1 26 (Revenue/ EPS)
+35.15%
/-33.15%
Implied change from Q2 25 (Revenue/ EPS)
+10.40%
/+5.13%
Ultragenyx Pharmaceutical Inc. earnings per share and revenue
On May 05, 2026, RARE reported earnings of -1.84 USD per share (EPS) for Q1 26, missing the estimate of -1.53 USD, resulting in a -19.49% surprise. Revenue reached 136.00 million, compared to an expected 161.95 million, with a -16.02% difference. The market reacted with a +3.68% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 14 analysts forecast an EPS of -1.23 USD, with revenue projected to reach 183.81 million USD, implying an decrease of -33.15% EPS, and increase of 35.15% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Immuneering Corporation Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.21
Surprise
+18.29%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
aTyr Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.11
Surprise
+21.60%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
Rein Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.19
Surprise
+61.98%
CervoMed Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.79
Actual
-$0.86
Surprise
-8.09%
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were Ultragenyx Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Ultragenyx Pharmaceutical Inc. reported EPS of -$1.84, missing estimates by -19.49%, and revenue of $136.00M, -16.02% below expectations.
How did the market react to Ultragenyx Pharmaceutical Inc.'s Q1 2026 earnings?
The stock price moved up 3.68%, changed from $25.01 before the earnings release to $25.93 the day after.
When is Ultragenyx Pharmaceutical Inc. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Ultragenyx Pharmaceutical Inc.'s next earnings report?
Based on 14
analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$1.23 and revenue of $183.81M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement